Effect of home blood pressure monitoring for blood pressure control in hypertensive patients taking multiple antihypertensive medications including fimasartan (the FORTE study)

Table 2 Effect of Home Blood Pressure Monitoring on Blood Pressure Control

	Odds ratio		P-value
	Point Estimate	95% CI	P-value
Age (years)	1.013	(1.005, 1.022)	0.0022
Sex	0.772	(0.632, 0.943)	0.0111
Target organ damage^a	0.870	(0.668, 1.133)	0.3005
Home sphygmomanometers at baseline	0.959	(0.759, 1.212)	0.7262
Baseline SBP	0.990	(0.983, 0.997)	0.0066
Baseline DBP	0.991	(0.981, 1.001)	0.0845
Dyslipidemia^b	0.968	(0.749, 1.252)	0.8046
FBS ≥100 mg/dL	0.715	(0.550, 0.929)	0.0121
Central obesity (men ≥90 cm, women ≥80 cm)	1.237	(0.993, 1.542)	0.0578
Family history of cardiovascular disease (men < 55 years, women < 65 years)	1.436	(0.875, 2.357)	0.1519
Intervention vs. control	0.836	(0.694, 1.007)	0.0586

SBP systolic blood pressure, DBP diastolic blood pressure, FBS fasting blood glucose, BMI body mass index, eGFR estimated glomerular filtration rate, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol
^aTarget organ damage was defined as a composite of 1) stroke, transient ischemic attack, or vascular dementia; 2) left ventricular hypertrophy, angina, myocardial infarction, or heart failure; 3) albuminuria (albumin level > 30 mg/g) or chronic kidney disease (eGFR < 60 mL/min/1.73 m²); 4) peripheral vascular disease (ankle-brachial index < 0.9), pulse wave velocity > 10 m/sec, intimal thickness of the carotid artery > 1.0 mm, or large artery disease; and 5) stage 3 or 4 hypertensive retinopathy
^bDyslipidemia was defined as total cholesterol level ≥ 230 mg/dL, LDL-C level ≥ 150 mg/dL, HDL-C level < 40 mg/dL, or triglyceride ≥200 mg/dL

ISSN: 2056-5909